<?xml version="1.0" encoding="UTF-8"?>
<p>Minocycline showed high efficacy in animal models and 
 <italic>in vitro</italic> studies for the treatment of JEV.
 <sup>
  <xref rid="bibr82-1759720X20947296" ref-type="bibr">82</xref>,
  <xref rid="bibr83-1759720X20947296" ref-type="bibr">83</xref>
 </sup> A double-blind, RCT allocated 44 pediatric patients into a minocycline group or placebo group. The results demonstrated minocycline significantly reduced the duration of unconsciousness, fever, and hospital-stay days, while neurologic deficits and mortality rate were unchanged.
 <sup>
  <xref rid="bibr84-1759720X20947296" ref-type="bibr">84</xref>
 </sup> Another RCT (
 <italic>n</italic> = 281) revealed that minocycline led to a trend of better outcomes, especially those who survived the first hospital day.
 <sup>
  <xref rid="bibr85-1759720X20947296" ref-type="bibr">85</xref>
 </sup>
</p>
